Industry Press Releases

Pulmatrix's New Life Sciences Animation Spotlights Inhaled Drug Delivery to Lungs

Tuesday, Jun 28, 2016
Pressreleases

Pulmatrix, Inc., a pharmaceutical company developing innovative inhaled drugs today announced the release of an animated life sciences video [ir.pulmatrix.com] to raise awareness of the problem of serious lung diseases and to describe promising new treatments.

"Millions of people struggle to breathe every day because of such diseases as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis (IPF)," explains Pulmatrix Chief Executive Officer Robert Clarke. "For them, the struggle for breath is a struggle for life."

Treating these diseases typically requires inhaling drugs into the lungs. But as the video animation describes, most currently available inhaled drugs have a serious limitation. Large amounts of the drugs never make it into the lung, where they are needed, because they get stuck in the throat. That not only reduces the effectiveness of the treatment, it also causes greater side effects.

The animation explains how Pulmatrix has tackled this problem by engineering particles that 'fly' far more easily into the lungs. "Our delivery system, which we call iSPERSE, has several potential advantages over most current approaches," says Chief Scientific Officer David Hava. "We believe that our delivery efficiency should allow patients who have trouble breathing to inhale the needed drugs into their lungs, with almost no deposition in the throat. We believe that the system should also be able to reliably deliver high doses, and be used with many types of drugs."

The animation shows how the size and shape of Pulmatrix's particles carries drugs deep into the lungs. It also describes Pulmatrix's pipeline of inhaled drugs. A product candidate named PUR0200 is a bronchodilator designed to help COPD patients breathe more easily. PUR1900 would be the first inhaled anti-fungal drug, addressing a significant unmet medical need for patients with cystic fibrosis and other diseases where lung fungal infections are common. The third product candidate, PUR1500, is being developed to treat idiopathic pulmonary fibrosis.

"Better drug delivery means better patient outcomes," says Dr. Clarke. "Our inhaled therapies should help patients breathe easier and improve their quality of life."

About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for lung diseases, including  opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare disease like cystic fibrosis.  Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 10, 2016. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact
Robert Clarke, CEO                                                    
(781) 357-2333                                                                      
rclarke@pulmatrix.com                                

William Duke, CFO
(781) 357-2333
wduke@pulmatrix.com

Chris Brinzey, Westwicke Partners
(339) 970-2843
IR@pulmatrix.com

 

Source : prnewswire.com